Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1

被引：16

作者：

Zhao, Xin-Yu ^{[1
,2
]}

Nie, Chun-Lai ^{[1
,2
]}

Liang, Shu-Fang ^{[1
,2
]}

Yuan, Zhu ^{[1
,2
]}

Deng, Hong-Xin ^{[1
,2
]}

Wei, Yu-Quan ^{[1
,2
]}

机构：

[1] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, 1 Keyuan 4th Rd, Chengdu 610041, Peoples R China

[2] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610041, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2012年 / 66卷 / 08期

关键词：

RNA interference; Polo-like kinase; Gemcitabine; POLO-LIKE-KINASE; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; EXPRESSION PATTERNS; PROSTATE-CANCER; EARLY EVENT; IN-VITRO; APOPTOSIS; POLO-LIKE-KINASE-1; CHEMOSENSITIVITY;

D O I：

10.1016/j.biopha.2012.01.003

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Specific PLK1 silencing may be an effective gene therapy modality of treating PLK1-overexpressed cancers. In this study, we first explored the anticancer efficacy of three different short hairpin-expressing plasmids targeting PLK1 in animal model, and then determined the combination therapy effect of gemcitabine with PLK1-shRNA as an adjuvant. Transfection of the PLK1-shRNAs to A549 lung cancer cells induced significant PLK1 depletion, growth inhibition and apoptosis. In vivo administration of PLK1-shRNA constructs to tumor-bearing mice resulted in xenograft regression. Moreover, the combination of PLK1-shRNA plus low-dose gemcitabine (GEM) produced an additive antitumor activity on the lung tumors owing to an inhibition of cancer cell survival and augmented apoptosis. These results indicated a feasible bio-chemotherapeutic strategy for cancer. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：597 / 602

页数：6

共 40 条

[1]

RNA interference: Biology, mechanism, and applications [J].